A radiopharmaceutical used to treat bone pain caused by cancer metastases.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Resche et al., "Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial," Journal of Clinical Oncology, vol.
Radionuclide Physical Energy Decay half-life max (MeV) Phosphorous-32 14.3 days 1.71 [beta] ([sup.32]P) Strontium-89 50.5 days 1.46 [beta] ([sup.89]P) Samarium-153 46.3 hours 0.84 [beta] and [gamma] ([sup.153]Sm) Radium-223 11.4 days 5.78 [alpha] and [gamma] ([sup.223]Ra) Radionuclide Mean range Carrier in tissue (mm) Phosphorous-32 7.9 Orthophosphate ([sup.32]P) Strontium-89 6.7 Chloride ([sup.89]P) Samarium-153 3.4 EDTMP ([sup.153]Sm) Radium-223 <0.1 Chloride ([sup.223]Ra) TABLE 3: Summary of clinical trials evaluating radiopharmaceuticals.
The most commonly used radiopharmaceuticals, both [beta]-emitters, initially approved in the US for treatment of bone metastases are Strontium-89 chloride or 89Sr (Metastron; GE Healthcare, Arlington Heights, IL) and Samarium-153 or 153Sm (Quadramet; EUSA Pharma, Oxford, UK).
In combining a radiopharmaceutical with chemotherapy to enhance antitumor effects, several phase I/II trials have explored the use of repeated doses of samarium-153 in combination with increasing doses of docetaxel.
Martindale, "A phase I study of samarium-153 ethylene-diaminetetramethylene phosphonate therapy for disseminated skeletal metastases," Journal of Clinical Oncology, vol.
Carrasquillo et al., "Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer," Journal of Clinical Oncology, vol.
Logothetis, "Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer," Journal of Clinical Oncology, vol.
The patient eventually became hormone refractory on complete hormone ablation and was started on Samarium-153 with a brief duration of PSA response.
Radiologist Edward Silberstein of the University of Cincinnati Medical Center has been investigating a host of radionuclides with a natural affinity for bone, including samarium-153, strontium-89, and rhenium-186.
The firm's plan to test a novel chemical preparation containing samarium-153 just received FDA approval.